Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1164 - Effects of positron emission tomography on patients with advanced squamous cell carcinoma of the head and neck


20 Dec 2015


Poster presentation 2


He-Yuan Hsieh


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


H. Hsieh1, J. Lin2, P. Lin2, Y. Liu2

Author affiliations

  • 1 Radiaiton Oncology, Taichung Veterans General Hospital, 40705 - Taichung/TW
  • 2 Radiation Oncology, Taichung Veterans General Hospital, 40705 - Taichung/TW


Abstract 1164


We investigated the prognostic values of pre-treatment (18)F-fluorodeoxyglucose positron emission tomography (PET) scan on patients with squamous cell carcinoma of the head and neck (SCCHN).


From August 2011 to May 2014, eighty-one patients with previously untreated, biopsy-proven, stage III-IV SCCHN were enrolled. They received a uniform outpatient weekly docetaxel-based induction chemotherapy followed by local treatment (either radiotherapy or surgery). Quantitative parameters of pre-treatment PET scan were collected, including the maximum standardized uptake value (SUVmax) of the primary tumor, the metabolic tumor volume (MTV) and the total lesion glycolysis (TLG). The receiver operating characteristic curves method was used to determine the best cut-off values (14 for SUVmax, 85 for MTV, and 305 for TLG, respectively).


After a median follow-up of 26 months, locoregional recurrence and distant metastasis were observed in 19 and 6 patients. There were 24 deaths. The 2-year overall survival rates were 65% and 90% for patients with SUVmax ≧ and < 14, respectively (HR, 2.84; 95% CI, 1.12 to 7.21; P = 0.028). MTV (62% vs. 82%, HR, 2.94; 95% CI, 1.29 to 6.70; P = 0.01) and TLG (65% vs. 85%, HR, 3.69; 95% CI, 1.45 to 9.39; P = 0.006) showed similar outcome. Multivariate Cox analysis also demonstrated the same results.


The SUVmax, MTV, and TLG of the pre-treatment PET scan are independent predictors of overall survival in patients with advanced SCCHN receiving docetaxel-based induction chemotherapy.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings